RadNet (RDNT)

• Market cap: $4.43B
• 1 day: -1.68%
• 5 days: -10.80%
• 1 month: -21.77%
• 3 months: -12.43%
• 6 months: -3.96%
• Year to date: -14.67%
• 1 year: 64.95%
• 5 years: 189.32%
• 10 years: 638.10%
• Sector: Healthcare
• Industry: Medical Laboratories

About: RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.

Employees: 10,288

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

93% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 28

22% more funds holding in top 10

Funds holding in top 10: 9 [Q2] → 11 (+2) [Q3]

20% more capital invested

Capital invested by funds: $3.64B [Q2] → $4.36B (+$716M) [Q3]

8% more funds holding

Funds holding: 275 [Q2] → 297 (+22) [Q3]

1.22% more ownership

Funds ownership: 83.69% [Q2] → 84.91% (+1.22%) [Q3]

1% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 100

59% less call options, than puts

Call options by funds: $7.5M | Put options by funds: $18.3M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $80 34% upside
• Avg. target: $86 44% upside
• High target: $94 57% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Jefferies Brian Tanquilut 50% 1-year accuracy 7 / 14 met price target	34% upside $80	Buy Maintained	15 Jan 2025
Barclays Andrew Mok 30% 1-year accuracy 19 / 63 met price target	42% upside $85	Overweight Maintained	4 Dec 2024
Truist Securities David Macdonald 59% 1-year accuracy 57 / 96 met price target	57% upside $94	Buy Maintained	29 Nov 2024